GlassScriptPhysician profile
Michael P Tan
NPI 1760419204
$9,659.72
in general payments reported to CMS, 2019-2025
32 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,794 · 2020: $905 · 2021: $1,472 · 2022: $1,409 · 2023: $901 · 2024: $1,497 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,884 · Education: $190 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,883.59 |
| Education | $190.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,942.43 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Mdd US Operations, LLC | $1,291.74 | 2019-2025 | Gocovri, Gocovri |
| Neurocrine Biosciences, INC. | $905.36 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $801.33 | 2022-2025 | Austedo Xr, Austedo Xr |
| Avanir Pharmaceuticals, INC. | $689.29 | 2019-2022 | |
| Lundbeck LLC | $585.76 | 2019-2025 | Rexulti, Vyepti |
| Acadia Pharmaceuticals INC | $467.32 | 2019-2025 | Nuplazid |
| Abbvie INC. | $465.41 | 2021-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $304.68 | 2020-2025 | Uplizna |
| Amneal Pharmaceuticals LLC | $294.83 | 2019-2025 | Rytary, Crexont |
| Jazz Pharmaceuticals INC. | $288.92 | 2022-2025 | Epidiolex |
| Sunovion Pharmaceuticals INC. | $242.02 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $211.58 | 2020-2022 | |
| Greenwich Biosciences, INC. | $209.39 | 2020-2021 | |
| Adamas Pharmaceuticals, INC. | $172.23 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $151.33 | 2023-2025 | Rexulti, Nuedexta |
| Sumitomo Pharma America, INC. | $135.11 | 2023-2024 | Aptiom |
| Livanova USA, INC. | $75.52 | 2021-2022 | |
| Kyowa Kirin, INC. | $62.17 | 2022-2024 | Nourianz |
| Acorda Therapeutics, INC | $46.02 | 2019-2020 | |
| Boston Scientific Corporation | $40.47 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Genzyme Corporation | $37.35 | 2019 | |
| Pfizer INC. | $33.24 | 2021 | |
| Ani Pharmaceuticals, INC. | $32.67 | 2025 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $28.28 | 2024 | Ponvory |
| Eisai INC. | $24.98 | 2024 | |
| Biogen, INC. | $22.34 | 2021 | |
| Sk Life Science, INC. | $20.80 | 2025 | |
| Argenx US, INC. | $20.46 | 2025 | Vyvgart Hytrulo |
| Tanabe Pharma America, INC. | $20.22 | 2022 | |
| Medtronic, INC. | $18.29 | 2022 | |
| Scilex Pharmaceuticals INC. | $18.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.